Biblio

Found 21 results
Filters: Author is Vanderah, Todd W and Keyword is Male  [Clear All Filters]
2020
Doyle TM, Janes K, Chen Z, Grace PM, Esposito E, Cuzzocrea S, Largent-Milnes TM, Neumann WL, Watkins LR, Spiegel S et al..  2020.  Activation of sphingosine-1-phosphate receptor subtype 1 in the central nervous system contributes to morphine-induced hyperalgesia and antinociceptive tolerance in rodents.. Pain. 161(9):2107-2118.
Bartlett MJ, So LY, Szabò L, Skinner DP, Parent KL, Heien ML, Vanderah TW, Polt R, Sherman SJ, Falk T.  2020.  Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model.. BMC Res Notes. 13(1):149.
2019
Thompson AL, Largent-Milnes TM, Vanderah TW.  2019.  Animal Models for the Study of Bone-Derived Pain.. Methods Mol Biol. 1914:391-407.
Khanna R, Patwardhan A, Yang X, Li W, Cai S, Ji Y, Chew LA, Dorame A, Bellampalli SS, Schmoll RW et al..  2019.  Development and Characterization of An Injury-free Model of Functional Pain in Rats by Exposure to Red Light.. J Pain. 20(11):1293-1306.
Hay M, Polt R, Heien ML, Vanderah TW, Largent-Milnes TM, Rodgers K, Falk T, Bartlett MJ, Doyle KP, Konhilas JP.  2019.  A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction.. J Pharmacol Exp Ther. 369(1):9-25.
Chen Z, Doyle TM, Luongo L, Largent-Milnes TM, Giancotti LAntonio, Kolar G, Squillace S, Boccella S, Walker JK, Pendleton A et al..  2019.  Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain.. Proc Natl Acad Sci U S A. 116(21):10557-10562.
2018
Pandit V, Khan M, Zakaria ERasheid, Largent-Milnes TM, Hamidi M, O'Keeffe T, Vanderah TW, Joseph B.  2018.  Continuous remote ischemic conditioning attenuates cognitive and motor deficits from moderate traumatic brain injury.. J Trauma Acute Care Surg. 85(1):48-53.
2016
Ramos-Colon CN, Lee YSun, Remesic M, Hall SM, LaVigne J, Davis P, Sandweiss AJ, McIntosh MI, Hanson J, Largent-Milnes TM et al..  2016.  Structure-Activity Relationships of [des-Arg(7)]Dynorphin A Analogues at the κ Opioid Receptor.. J Med Chem. 59(22):10291-10298.
2015
Deekonda S, Wugalter L, Kulkarni V, Rankin D, Largent-Milnes TM, Davis P, BassiriRad NM, Lai J, Vanderah TW, Porreca F et al..  2015.  Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.. Bioorg Med Chem. 23(18):6185-94.
Giri AKumar, Apostol CR, Wang Y, Forte BL, Largent-Milnes TM, Davis P, Rankin D, Molnar G, Olson KM, Porreca F et al..  2015.  Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.. J Med Chem. 58(21):8573-83.
2013
Podolsky AT, Sandweiss A, Hu J, Bilsky EJ, Cain JP, Kumirov VK, Lee YSun, Hruby VJ, Vardanyan RS, Vanderah TW.  2013.  Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.. Life Sci. 93(25-26):1010-6.
2012
De Felice M, Melchiorri P, Ossipov MH, Vanderah TW, Porreca F, Negri L.  2012.  Mechanisms of Bv8-induced biphasic hyperalgesia: increased excitatory transmitter release and expression.. Neurosci Lett. 521(1):40-5.
Tumati S, Largent-Milnes TM, Keresztes A, Ren J, Roeske WR, Vanderah TW, Varga EV.  2012.  Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.. J Neuroimmunol. 244(1-2):23-31.
Tumati S, Largent-Milnes TM, Keresztes AI, Yamamoto T, Vanderah TW, Roeske WR, Hruby VJ, Varga EV.  2012.  Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.. Eur J Pharmacol. 684(1-3):64-70.
2011
Lee YSun, Kulkarani V, Cowell SM, Ma S-W, Davis P, Hanlon KE, Vanderah TW, Lai J, Porreca F, Vardanyan R et al..  2011.  Development of potent μ and δ opioid agonists with high lipophilicity.. J Med Chem. 54(1):382-6.
Yamamoto T, Nair P, Largent-Milnes TM, Jacobsen NE, Davis P, Ma S-W, Yamamura HI, Vanderah TW, Porreca F, Lai J et al..  2011.  Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.. J Med Chem. 54(7):2029-38.
Hanlon KE, Herman DS, Agnes RS, Largent-Milnes TM, Kumarasinghe IR, Ma SW, Guo W, Lee Y-S, Ossipov MH, Hruby VJ et al..  2011.  Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain.. Brain Res. 1395:1-11.
2010
Lozano-Ondoua AN, Wright C, Vardanyan A, King T, Largent-Milnes TM, Nelson M, Jimenez-Andrade JMiguel, Mantyh PW, Vanderah TW.  2010.  A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.. Life Sci. 86(17-18):646-53.
2008
Tumati S, Milnes TLargent, Yamamura HI, Vanderah TW, Roeske WR, Varga EV.  2008.  Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia.. Eur J Pharmacol. 601(1-3):207-8.
Vanderah TW, Largent-Milnes T, Lai J, Porreca F, Houghten RA, Menzaghi F, Wisniewski K, Stalewski J, Sueiras-Diaz J, Galyean R et al..  2008.  Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors.. Eur J Pharmacol. 583(1):62-72.
Largent-Milnes TM, Guo W, Wang H-Y, Burns LH, Vanderah TW.  2008.  Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.. J Pain. 9(8):700-13.